KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Other Non-Current Assets (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Other Non-Current Assets for 7 consecutive years, with $79.3 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets rose 136.46% to $79.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $79.3 million through Dec 2025, up 136.46% year-over-year, with the annual reading at $79.3 million for FY2025, 136.46% up from the prior year.
  • Other Non-Current Assets hit $79.3 million in Q4 2025 for Royalty Pharma, down from $86.6 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $86.6 million in Q3 2025 to a low of $3.9 million in Q1 2022.
  • Historically, Other Non-Current Assets has averaged $29.9 million across 5 years, with a median of $28.7 million in 2023.
  • Biggest five-year swings in Other Non-Current Assets: crashed 83.99% in 2024 and later skyrocketed 717.89% in 2025.
  • Year by year, Other Non-Current Assets stood at $4.1 million in 2021, then surged by 614.81% to $29.6 million in 2022, then tumbled by 77.99% to $6.5 million in 2023, then soared by 414.17% to $33.5 million in 2024, then surged by 136.46% to $79.3 million in 2025.
  • Business Quant data shows Other Non-Current Assets for RPRX at $79.3 million in Q4 2025, $86.6 million in Q3 2025, and $85.5 million in Q2 2025.